The ET-9 signature is independent of patient age, ethnicity, disease stage and proliferation, and correlates with patient outcome in triple-negative breast cancer, HER2+, lymph node positive, chemotherapy treated, and brain metastatic breast cancers. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.